AU565 - Cell Line (ID:50091)
HMS LINCS ID: | 50091 |
Name: | AU565 |
Alternative Names: | AU-565 |
LINCS ID: | LCL-1462 |
Alternative ID: | CLO_0001769 |
Parent Cell Line: | |
Reference Source: | ATCC CRL-2351 |
Organism: | Homo sapiens |
Organ: | breast |
Tissue: | |
Cell Type: | |
Details of Cell Type: | |
Donor Sex: | female |
Donor Age: | |
Donor Ethnicity: | |
Donor Health Status: | |
Disease: | DOID:3458, adenocarcinoma |
Details of Disease: | breast adenocarcinoma |
Production Details: | |
Genetic Modification(s): | none |
Known Mutations: | |
Citation Information for Mutations: | COSS910704 |
Verification Reference Profile: | |
Growth Properties: | adherent |
Recommended Culture Conditions: | From MGH/CMT as specified by cell provider: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate, 90%; fetal bovine serum, 10%. Subculturing: Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks. Subcultivation ratio: A subcultivation ratio of 1:4 to 1:6 is recommended |
Relevant Citations: | |
Usage Note: | |
Comments: | |
Date Publicly Available: | 2012-07-31 |
Most Recent Update: | 2016-04-04 |
Datasets:
HMS Dataset ID | Dataset Title | HMS Dataset Type |
---|---|---|
20120 | Metrics other than potency reveal systematic variation in responses to cancer drugs | Analysis |
20136 | Breast cell line dose response to target inhibition measured by high throughput microscopy | Microscopy/Imaging |
20137 | Basal profile of receptor tyrosine kinase signaling network measured by ELISA | ELISA |
20138 | Cell signaling response to growth factors measured by high throughput microscopy | Microscopy/Imaging |
20139 | Cell signaling response to cytokines measured by high throughput microscopy | Microscopy/Imaging |
20140 | Cell signaling response to growth factors measured by ELISA | ELISA |
20268 | Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. | Analysis |
20269 | Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. | Analysis |
20354 | Breast Cancer Profiling Project, Drug Sensitivity phase II: Fixed-cell GR measures of 33 breast cell lines and PDX lines to 16 small molecule perturbagens from library plate II. Dataset 1 of 2: Normalized growth rate inhibition values | Microscopy/Imaging |
20355 | Breast Cancer Profiling Project, Drug Sensitivity phase II: Fixed-cell GR measures of 33 breast cell lines and PDX lines to 16 small molecule perturbagens from library plate II. Dataset 2 of 2: Calculated dose response metrics | Analysis |
20370 | Breast Cancer Profiling Project – Proteomics 3: 1 total proteome dataset for a 27-cell line breast cancer panel under basal conditions | Proteomics |
Batch Information:
HMS LINCS Batch ID | Provider | Provider Catalog ID | Provider Batch ID |
---|---|---|---|
50091-1 | ATCC | CRL-2351 | |
50091-2 | Mario Niepel (Harvard Medical School) | ||
50091-3 | ATCC | CRL-2351 |